Vaccination against Epstein-Barr virus: current progress and future strategies.
A vaccine derived from the high-molecular-weight glycoprotein (gp340) component of the Epstein-Barr (EB) virus membrane antigen conferred complete protection against a 100% lymphomagenic dose of EB virus in the cottontop tamarin, the animal of choice for experiments with EB virus. The membrane-antigen gene has already been cloned, and the development of a vaccine for use in man should now be possible. Such a vaccine could be tested first against infectious mononucleosis, because the effectiveness of vaccination would become evident in a relatively short time. Field trials against Burkitt's lymphoma and nasopharyngeal cancer could follow.
Epstein
M A
MA
D000818:Animals; D000956:Antigens, Viral / Q000276:immunology; D002051:Burkitt Lymphoma / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005544:Forecasting; D006023:Glycoproteins / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins / Q000276:immunology; D008970:Molecular Weight; D009303:Nasopharyngeal Neoplasms / Q000517:prevention & control; D014611:Vaccination / Q000639:trends*; D014763:Viral Matrix Proteins; D014765:Viral Vaccines / Q000276:immunology*
D000956:Antigens, Viral; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D006023:Glycoproteins; D008565:Membrane Proteins; D014763:Viral Matrix Proteins; D014765:Viral Vaccines